Innova Captab Limited — Q1 FY26 earnings call

Call held 8 Aug 2025

Management summary

Innova Captab reported strong financial performance in Q1 FY26, with consolidated revenue growing 19% and EBITDA up 28% year-on-year, despite API price drops. The company reorganized its business into CDMO and branded generics, with the new Jammu facility contributing significantly and nearing PAT breakeven. Management expressed confidence in continued growth driven by client traction and geographical expansion, though API price volatility remains a watch item.

Highlights

  • Consolidated revenue of ₹351.5 crores, up 19% YoY.

  • EBITDA grew 28% to ₹56.6 crores.

  • EBITDA margins improved to 16.1% from 15.1% in Q1 FY25.

  • PAT increased 5% YoY to ₹31 crores, with a PAT margin of 8.8%.

  • CDMO business contributed 71% of total revenue, growing 8% YoY to ₹249.5 crores.

  • Branded Generic business delivered stellar growth of 59% to ₹101.2 crores.

  • Jammu greenfield facility commercialized in January 2025, generated ₹60 crores in Q1 FY26.

  • Operational breakeven for Jammu facility achieved at ₹60-65 crores revenue, with PAT breakeven targeted at ₹100 crore quarterly revenue.

Concerns

  • API price volatility and decline

Key financials

  1. Revenue ₹351.5 Cr +19%YoY
  2. EBITDA ₹56.6 Cr +28%YoY
  3. EBITDA Margin 16.1%
  4. PAT ₹31 Cr +5%YoY
  5. PAT Margin 8.8%

What they filed

Q1 FY27: revenue up 33.8%, net profit up 41.9% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue318 316 315 352 380 +19%450 +42%448 +42%471 +34%
EBITDA50 47 48 52 52 +4%69 +47%65 +35%73 +40%
Net profit35 34 30 31 30 −14%42 +24%38 +27%44 +42%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

Share of Revenue
₹350.7 Cr Total
  • CDMO Business ₹249.5 Cr 71.1%
  • Branded Generic Business ₹101.2 Cr 28.9%

Guidance & targets

Capacity

  • Jammu facility revenue Capacity · FY26 · Medium confidence ₹400 crores
    Okay. See, the Jammu revenue anticipated for this financial year as we submitted in our earlier discussions is ₹400 crores.

    — Lokesh Bhasin, Chief Financial Officer

  • Jammu facility revenue level Capacity · Medium confidence ₹100 crore
    So we have already -- in the last tele call, we also covered that it is how fast we reach at 100 crore level at Jammu facility, that is our priority.

    — Vinay Lohariwala, Managing Director

  • Baddi Cephalosporin business transfer Capacity · Medium confidence 100% towards export-oriented business
    But as we progress, our planning is that the Baddi Cephalosporin will be 100% move towards the export-oriented business.

    — Vinay Lohariwala, Managing Director

  • Baddi business transfer to Jammu Capacity · Q3 or Q4 this year · High confidence closed
    So I think the transfer activity will go up to the third or max by up to fourth quarter. This year, all these events will be closed.

    — Vinay Lohariwala, Managing Director

Profitability

  • Jammu facility PAT breakeven Profitability · quarterly · High confidence ₹100-105 crores
    So if I talk at a PAT level, as Vinay sir earlier said that our internal target is to reach at 100 crore quarterly revenue. So this is a level where somewhere around 100 crores, 105 crores of quarterly revenue, we should be able to break even at PAT level.

    — Lokesh Bhasin, Chief Financial Officer

  • Jammu facility operational breakeven Profitability · High confidence ₹60-65 crores
    And operational level is somewhere around 60-65 crores of revenue.

    — Vinay Lohariwala, Managing Director

  • Jammu facility PAT positive Profitability · by the end of the year · High confidence PAT positive
    And we're hopeful that by the end of the year, we will be the PAT positive as well.

    — Vinay Lohariwala, Managing Director

Revenue

  • Overall revenue guidance Revenue · Low confidence retain guidance
    But as I said, that we are monitoring the situation very closely. And hopefully, if the prices stabilize, we should be able to retain our guidance.

    — Lokesh Bhasin, Chief Financial Officer

Risks & concerns

  • API price volatility and decline

    high

    API prices, especially in the antibody segment (e.g., potassium clavulanate), have seen significant declines (>20%), creating market turmoil and impacting revenue.

    Management acknowledged

  • Capacity expansion leading to pricing pressure in formulation space

    medium

    Analyst questioned if the formulation space is seeing similar overcapacity and pricing pressure as APIs, given new capacities from Innova and competitors; management cited market growth and fiscal incentives.

    Analyst downplayed

  • Impact of GST rate changes on incentives

    low

    Analyst asked about the impact on the fixed ₹75 crore GST incentive if GST rates for pharma products were to change; management stated it's hypothetical and unlikely to happen suddenly.

    Analyst downplayed

Areas of evasion (4)

  • Segmental breakup for previous quarter
  • Specific breakdown of Baddi transfer within Jammu revenue
  • Quantification of API price impact on guidance
  • Schedule M implications/channel inventory

Q&A highlights

0 direct, 1 evasive
Jammu plant revenue contribution and Baddi transfer portion Partial
So that is a bit difficult to comment on, but the overall revenue from the Jammu is 60 crores.

Investors sought clarity on how much of the new plant's revenue is incremental versus transferred from existing operations, which impacts the true growth picture.

Asked by Parth Mehta

Impact of API price decline on overall revenue guidance Partial
So the exact impact of API reduction as of now may not be able to reveal or share. But yes, it is slightly having an impact on our overall revenue. But as I said, that we are monitoring the situation very closely. And hopefully, if the prices stabilize, we should be able to retain our guidance.

API price volatility is a key risk, and management's inability to quantify its impact or firmly reconfirm guidance creates uncertainty for future revenue projections.

Asked by Sudarshan Padmanabhan

Schedule M implementation and channel inventory in formulation space Evasive
This is difficult to comment, sir, on these questions.

Schedule M changes could significantly alter market dynamics, and management's reluctance to discuss potential channel inventory build-up leaves a gap in understanding market health and competitive landscape.

Asked by Saket

2 min read 6 chapters

Detailed narrative

Strong Q1 FY26 Performance Despite Headwinds

Innova Captab reported a robust Q1 FY26, with consolidated revenue reaching ₹351.5 crores, marking a 19% year-on-year growth. EBITDA saw a significant 28% increase to ₹56.6 crores, improving EBITDA margins to 16.1% from 15.1% in Q1 FY25. Net Profit After Tax (PAT) grew 5% YoY to ₹31 crores, with a PAT margin of 8.8%, despite increased depreciation and finance expenses.

Business Reorganization and Segmental Growth

The company reorganized its operations into two streamlined verticals: CDMO and Branded Generics. The CDMO business, which includes legacy operations, Sharon business, and part of the international branded generic portfolio, contributed 71% of total revenue, growing 8% YoY to ₹249.5 crores. The Branded Generic business, encompassing domestic and international front-end operations, delivered stellar growth of 59% YoY, reaching ₹101.2 crores, primarily driven by export markets and broader geographic reach.

Jammu Greenfield Facility Ramp-up and Breakeven Targets

The new greenfield facility in Kathua, Jammu, commercialized in January 2025, generated ₹60 crores in revenue during Q1 FY26. Management stated that the facility has already achieved operational breakeven at ₹60-65 crores revenue, with an EBITDA loss of hardly ₹1 crore. The internal target for PAT breakeven is set at ₹100-105 crores quarterly revenue, and the company is hopeful to be PAT positive by the end of the year, aided by fiscal incentives.

API Price Volatility and Impact on Outlook

A significant concern raised was the sharp decline in API prices, with some key raw materials like potassium clavulanate crashing over 20% (from ₹18,500 to ₹13,000). While Innova Captab operates on a pass-through model with fixed and percentage-based components, such drastic drops impact absolute per-unit realizations. Management acknowledged that this volatility is 'slightly having an impact on our overall revenue' and stated that retaining the overall revenue guidance is contingent on price stabilization.

Strategic Advantages and Capacity Utilization

The Jammu facility, built with a ₹480 crore investment, offers a competitive edge due to its modern CGMP norms, automation, and zero-defect focus, attracting positive customer feedback. The transfer of Baddi's Cephalosporin business to export-oriented operations is planned to be 100%, with the overall transfer activity to Jammu expected to conclude by Q3/Q4 FY26. Despite the ₹60 crore revenue in Q1 FY26, the Jammu plant's asset utilization is currently very low, estimated at less than 5% of its potential top revenue of ₹1,500-2,000 crores.

GST Incentives and Regulatory Environment

The company benefits from a fixed GST incentive of approximately ₹75 crores. Management clarified that if GST rates were to decrease (e.g., from 12% to 8%), a higher sales volume (₹900 crores vs current ₹600-620 crores) would be required to fully utilize the incentive. Conversely, an increase to 18% would make the incentive achievable with lower sales (₹400 crores). However, management deemed questions about sudden GST rate changes as hypothetical and unlikely to occur.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls